Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 11-20 of 24

Page
per page
  1. MK-2461
    A8476 MK-2461
    Target: FLT3|PDGFR|MET|Ron
    Summary: C-Met (WT/mutants) inhibitor
      ≥24.8 mg/mL
  2. Flumatinib mesylate
    A8691 Flumatinib mesylate
    Summary: PDGRFβ inhibitor
      Soluble in DMSO
  3. Sunitinib
    B1045 Sunitinib
    Summary: RTK inhibitor
      insoluble in H2O; ≥19.9 mg/mL
  4. Imatinib hydrochloride
    A3487 Imatinib hydrochloride
    Summary: V-Abl/c-Kit/PDGFR inhibitor
      Soluble in DMSO
  5. Toceranib
    A3879 Toceranib
    Summary: c-Kit/VEGFR/PDGFR inhibtor
      soluble in DMSO
  6. ZM323881
    A3954 ZM323881
    Target: VEGFR
    Summary: VEGFR-2/KDR inhibitor,potent and selective
      Soluble in DMSO
  7. Sorafenib
    A3009 Sorafenib
     2 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥23.25 mg/mL
  8. Pazopanib (GW-786034)
    A3022 Pazopanib (GW-786034)
    Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
  9. Amuvatinib (MP-470, HPK 56)
    A4237 Amuvatinib (MP-470, HPK 56)
    Summary: Tyrosine kinase inhibitor
      ≥22.4 mg/mL
  10. JNJ-10198409
    C5737 JNJ-10198409
    Summary: inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase
      ≤10 mg/mL

Items 11-20 of 24

Page
per page